This video makes reference to guidelines produced by the "National Institute for Health and Care Excellence" in the UK, also referred to as "NICE". Please note that the content on this channel reflects my professional interpretation/summary of the guidance and that I am in no way affiliated with, employed by or funded/sponsored by NICE.

My name is Fernando Florido and I am a GP in the United Kingdom. In this video I go through some of the statements made by NICE in the guidelines “Chronic kidney disease: assessment and management” or NG203, published on 25 August 2021, explaining why these statements were made.

Tracks:

00:00 – Introduction and welcome
00:54 – Muscle mass and eGFR
02:24 – Protein and eGFR
03:18 – ACR and EMU
04:01 – ACEIs/ARBs and UEs
05:26 – CKD bleeding risk
06:35 – Anaemia of CKD
07:38 – Ferritin in CKD
08:27 – IV iron in haemodialysis
08:47 – PTH and anaemia
10:41 – Blood transfusions in CKD
11:19 – ACEIs/ARBs and ESAs
12:09 – Hyperphosphataemia
13:26 – Bone metabolism and osteoporosis in CKD
14:50 – Calcitriol and alfacalcidol in CKD
16:38 – Metabolic acidosis in CKD
17:28 – Thank you and good-bye

There is a podcast version of this and other videos that you can access here:

Primary Care guidelines podcast:

• Redcircle: [ Ссылка ]
• Spotify: [ Ссылка ]
• Apple podcasts: [ Ссылка ]

Full NICE guideline on CKD:

• Website: [ Ссылка ] or as

• Or download here: [ Ссылка ]

CKD visual summaries:
• Websites:
o Identifying CKD:
[ Ссылка ]
o Managing proteinuria:
[ Ссылка ]
o Phosphate binders:
[ Ссылка ]
• Or download here:

o Identifying CKD: [ Ссылка ]

o Managing proteinuria:
[ Ссылка ]

o Phosphate binders:
[ Ссылка ]


CKD tables- 1&2
• Download: [ Ссылка ]

NICE HTA guideline:

• Full guideline: [ Ссылка ]
• Flowchart: [ Ссылка ]
• Shorts:
o [ Ссылка ]
o [ Ссылка ]
o [ Ссылка ]


SGLT2 inhibitors for adults with CKD and type 2 diabetes, see chronic kidney disease in NICE's guideline on type 2 diabetes in adults.

• Summary of guidance: CKD section of diabetes guideline 1.8.17
For adults with type 2 diabetes and CKD who are taking an ARB or an ACE inhibitor (titrated to the highest licensed dose that they can tolerate), offer an SGLT2 inhibitor (in addition to the ARB or ACE inhibitor) if:
• ACR is over 30 mg/mmol and
• they meet the criteria in the marketing authorisation (including relevant estimated glomerular filtration rate [eGFR] thresholds).
• Website: Diabetes guideline:
[ Ссылка ]

NICE's technology appraisal guidance on dapagliflozin for treating chronic kidney disease.

• Website:
[ Ссылка ]
• Or download here:
[ Ссылка ]


NICE's technology appraisals on sodium zirconium cyclosilicate and patiromer.

• Website:
o Zirconium: [ Ссылка ]
o Patiromer: [ Ссылка ]

• Or download here:
o Zirconium:
[ Ссылка ]
o Patiromer: [ Ссылка ]


NICE's guideline on cardiovascular disease: risk assessment and reduction, including lipid modification for the use of statins in adults with CKD.

• Website: [ Ссылка ]

• Or download here:
[ Ссылка ]


MHRA safety advice on recombinant human erythropoietins:

• Website:
[ Ссылка ]
• Summary of advice:
Recombinant human erythropoietins: new advice for prescribing
Over-correction of haemoglobin concentration may increase the risk of death and serious cardiovascular events in patients with chronic kidney disease; it may increase the risk of thrombosis and related complications in patients with cancer.
4-variable Kidney Failure Risk Equation
• Download:
[ Ссылка ]

свернуть